Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Citius Pharmaceuticals, Inc. (CTXR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
4Distinct source URLs
11High confidence
0.766Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Citius Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
BIORASI-LLC
BIORASI-LLC
92%
In May 2022, the Company selected Biorasi, LLC ("Biorasi"), a global clinical research organization ("CRO"), to help expand the Company's Phase 3 Mino-Lok trial by implementing additional sites outsi…
olution in Phase 3 clinical development, which if approved, would be used to treat catheter-related bloodstream infections, and is expected to be amortized on a straight-line basis over a period of c…
Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: olution in Phase 3 clinical development, which if approved, would be used to treat catheter-related bloodstream infec…
H-C-WAINWRIGHT-AND-CO-LLC
H-C-WAINWRIGHT-AND-CO-LLC
90%
H.C. Wainwright and Co., LLC ("Wainwright") acted as the Company's exclusive placement agent in connection with the Offer
INTEGRIS-PHARMA-S-A
INTEGRIS-PHARMA-S-A
90%
On October 7, 2025, Citius Oncology entered into an exclusive distribution agreement with Integris Pharma S.A
ER-KIM
ER-KIM
85%
On February 11, 2026, Citius Oncology announced an exclusive distribution agreement with Uniphar
UNIPHAR
UNIPHAR
85%
On February 11, 2026, Citius Oncology announced an exclusive distribution agreement with Uniphar
Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect…
adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
Reciprocal relationship from SLB graph: Reciprocal relationship from CTXR graph: Reciprocal relationship from SLB graph: each ChampionX share. Excluding its Drilling Technologies business, which was …
s, NoveCite had to maintain Novellus’s ownership at % by issuing additional shares to Novellus. In July 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). In this transact…
Reciprocal relationship from CTOR graph: Reciprocal relationship from CTXR graph: s, NoveCite had to maintain Novellus’s ownership at % by issuing additional shares to Novellus. In July 2021, Novellu…
adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
Reciprocal relationship from MCK graph: Reciprocal relationship from CTXR graph: adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect…
BROOKLYN-IMMUNOTHERAPEUTICS-INC
BROOKLYN-IMMUNOTHERAPEUTICS-INC
62%
y 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). Pursuant to this transaction, the NoveCite license was assumed by Brooklyn with all original terms and conditions. In …
DIAGNOSIS-RELATED-GROUP
DIAGNOSIS-RELATED-GROUP
62%
adds the risk of import restrictions, and adds the risk of political and environmental uncertainties that might affect those countries; ● Drug manufacturers are subject to ongoing periodic unannounce…
EISAI-CO-LTD
EISAI-CO-LTD
62%
y 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). Pursuant to this transaction, the NoveCite license was assumed by Brooklyn with all original terms and conditions. In …
ETERNA-THERAPEUTICS-INC
ETERNA-THERAPEUTICS-INC
62%
y 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). Pursuant to this transaction, the NoveCite license was assumed by Brooklyn with all original terms and conditions. In …
LABORATORIES-LTD
LABORATORIES-LTD
62%
y 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). Pursuant to this transaction, the NoveCite license was assumed by Brooklyn with all original terms and conditions. In …
REPORT-CITIUS-PHARMACEUTICALS-INC
REPORT-CITIUS-PHARMACEUTICALS-INC
62%
error to previously issued financial statements. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation rec…
TENX-MERGER-SUB-INC
TENX-MERGER-SUB-INC
62%
12, 2024, Citius Pharma and Citius Oncology entered into a merger agreement with TenX Keane Acquisition, and its wholly owned subsidiary, TenX Merger Sub Inc (“Merger Sub”), whereby Merger Sub merged…
Citius Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CTXR-DEBT-8927
Warrants outstanding: 5142858
90%
xbrl warrant detail from xbrl 2025-09-10.
CTXR-DEBT-8928
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-09-30.
CTXR-DEBT
Debt stack $808,162
90%
Market cache reports total debt of $808,162.
Citius Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Citius Pharmaceuticals, Inc..
Citius Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
CTXR-OWNER-ARMISTICE-CAPITAL-LLC
ARMISTICE CAPITAL, LLC
90%
13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 15 tracked holders.
Citius Pharmaceuticals, Inc. Extended Supply Chain Network
